Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting

Caris Life Sciences (NASDAQ: CAI) will present five studies at the 2026 USCAP Annual Meeting in San Antonio, March 21–26, 2026.

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) will present five studies at the 2026 USCAP Annual Meeting in San Antonio, March 21–26, 2026. Presentations include one oral session and four posters across sarcomas, melanoma and GIST, using Caris' multimodal WES/WTS/IHC and real-world database. Research will be available at booth #512 and full abstracts will be posted on the company website after presentations.

Argus Mar 11 session

+0.43% close to close Open Argus

Details

News Market Reaction – CAI

On Mar 11, the day this news came out, CAI closed 0.43% above the previous close.

Data tracked by StockTitan Argus for the Mar 11 session.

Key Figures

Current Price: $18.52 52-week Range: $17.15–$56.215 Studies at USCAP: 5 studies +5 more

Current Price

$18.52

Pre-news trading level on 2026-03-11

52-week Range

$17.15–$56.215

52-week low and high before this news

Studies at USCAP

5 studies

One oral presentation and four posters at 2026 USCAP

Collaborating centers

Over 20 centers

Cancer centers and institutions across US and Europe

2025 Revenue

$812.0M

Full year 2025 revenue, up 97% YoY

2025 Revenue Growth

97%

Year-over-year revenue increase in 2025

Q4 2025 Revenue

$292.9M

Fourth quarter 2025 revenue

2025 Gross Margin

66%

Full year 2025 gross margin

Historical Context

5 past events · Latest: Mar 09

5 events

1. Mar 09

   AI signature launch

   24h Move

   +2.2%

   Launch of Caris AI Insights signature guiding first-line PDAC therapy choices.

2. Feb 26

   Clinical data update

   24h Move

   +4.7%

   Interim Achieve 1 data for Caris Detect multi-cancer early detection test.

3. Feb 26

   Correction notice

   24h Move

   +4.7%

   Clarifying Achieve 1 interim metrics for Caris Detect early detection assay.

4. Feb 26

   Earnings and outlook

   24h Move

   +4.7%

   Strong 2025 revenue growth, improved margins, and 2026 revenue outlook with product plans.

5. Feb 24

   AI signature launch

   24h Move

   +3.2%

   AI-driven capecitabine response signature added to Caris Molecular Tumor Board Report.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

whole exome sequencing (WES), whole transcriptome sequencing (WTS), ihc, programmed death-ligand 1 (pd-l1), +2 more

6 terms

whole exome sequencing (WES) medical

"database, comprised of Whole Exome Sequencing (WES), Whole Transcriptome"

Whole exome sequencing (WES) reads the portions of a person’s DNA that code for proteins — about the most critical pages in the body’s instruction manual. By focusing on these protein-making sections rather than the entire genome, WES helps identify changes that can cause disease, guide diagnosis, or point to targets for drugs. Investors care because WES can speed discovery, reduce clinical uncertainty, and create clearer paths to diagnostic tests and targeted treatments that drive commercial value.

whole transcriptome sequencing (WTS) medical

"comprised of Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), IHC"

Whole transcriptome sequencing (WTS) is a lab method that reads all the RNA messages inside a cell or tissue to show which genes are turned on or off, similar to collecting every email in an office to understand what tasks are being done. For investors, WTS matters because it can reveal disease mechanisms, identify drug targets or biomarkers, and improve patient selection or diagnostic tests—information that can change the commercial potential of therapies and diagnostics.

ihc medical

"Whole Transcriptome Sequencing (WTS), IHC and real-world clinical data, was used"

Immunohistochemistry (IHC) is a laboratory technique that uses labeled antibodies to detect and visually highlight specific proteins inside tissue samples, producing stained patterns pathologists can see under a microscope. For investors, IHC matters because it helps confirm whether a drug or diagnostic hits the intended target in real patient tissues and can support patient selection, clinical trial design and regulatory filings — essentially acting like a map that shows where a therapy is likely to work and reducing clinical and regulatory risk.

programmed death-ligand 1 (pd-l1) medical

"Interplay of Programmed Death-Ligand 1 (PD-L1) Expression in Gastrointestinal"

Programmed death‑ligand 1 (PD‑L1) is a protein found on the surface of some cells, including many cancer cells, that acts like an “off” switch for the immune system by telling immune cells not to attack. Investors care because PD‑L1 levels are used as a biomarker to predict whether patients are likely to benefit from certain immunotherapy drugs and can influence clinical trial results, regulatory approval, and the commercial potential of diagnostic tests and treatments.

gastrointestinal stromal tumor (gist) medical

"Programmed Death-Ligand 1 (PD-L1) Expression in Gastrointestinal Stromal Tumor (GIST):"

A gastrointestinal stromal tumor (GIST) is a type of tumor that starts in the walls of the digestive tract—most often the stomach or small intestine—arising from specific cells that help the gut’s muscles move. It matters to investors because GISTs are often treated with targeted drugs and surgery, so clinical trial results, regulatory approvals, or new therapies can directly affect pharmaceutical companies’ sales and a drugmaker’s future revenue, much like a single new product can change a company’s outlook.

ntrk-rearranged sarcomas medical

"Comprehensive Analysis of Adult NTRK-Rearranged Sarcomas: Clinical, Pathologic, and"

NTRK-rearranged sarcomas are a group of rare cancers in which a part of an NTRK gene becomes abnormally joined to another gene, creating a driver protein that tells cells to grow unchecked. For investors, these tumors matter because they can be treated with a specific class of drugs called TRK inhibitors; identifying and successfully treating such molecularly defined cancers can create clearly targeted drug markets and influence clinical trial design, regulatory approvals, and commercial potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVING, Texas, March 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, will collectively present five studies at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting in San Antonio, Texas to be held March 21-26, 2026.

Caris' robust multimodal database, comprised of Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), IHC and real-world clinical data, was used to generate the results being presented. The studies, including one oral presentation and four posters, will cover soft tissue and bone sarcomas, melanoma and gastrointestinal stromal tumors. These posters and presentation represent a collaborative effort between Caris and over 20 cancer centers and institutions across the United States and Europe.

"USCAP offers a great opportunity for pathologists to showcase the latest advances and publications in our industry. We're presenting across multiple topics, incorporating real‑world outcomes and uncovering insights that bring us closer to truly personalized treatment pathways," said Matthew Oberley, MD, PhD, SVP, Chief Clinical Officer and Pathologist-in-Chief at Caris.    

Oral Presentation:

• BCORL1::CREBBP Fusions Characterize an Aggressive Frequently Ossifying Bone and Soft Tissue Sarcoma with Predilection for the Clavicular Bone. Oral #808
  • Platform - Tuesday PM - Bone and Soft Tissue Pathology. March 24, 2026. Presentation Time:  2:00 PM – 2:15 PM CDT

Posters Include:

• Landscape and Molecular/Clinical Correlates of Pathogenic Gene Fusions in Melanoma: A Comprehensive Molecular Profiling Study. Poster #48
  • Poster II - Monday PM - Dermatopathology. March 23, 2026. Time:  1:00 PM – 4:30 PM CDT
• Comprehensive Analysis of Adult NTRK-Rearranged Sarcomas: Clinical, Pathologic, and Genomic Correlates. Poster #69
  • Poster II - Monday PM - Bone and Soft Tissue Pathology. March 23, 2026. Time:  1:00 PM – 4:30 PM CDT
• Secondary Genetic Alterations in Extraskeletal Myxoid Chondrosarcoma: Beyond NR4A3. Poster #70
  • Poster II - Monday PM - Bone and Soft Tissue Pathology. March 23, 2026. Time:  1:00 PM – 4:30 PM CDT
• Interplay of Programmed Death-Ligand 1 (PD-L1) Expression in Gastrointestinal Stromal Tumor (GIST): Correlation with Clinicopathologic Features, Comprehensive Genomic Profile, and Disease Outcome. Poster #63
  • Poster IV – Tuesday PM – Bone and Soft Tissue Pathology. March 24, 2026. Time:  1:00 PM – 4:30 PM CDT

Research highlights will be available onsite at Caris' booth #512. The full abstracts will be available on the Caris website following the presentations.

About Caris Life Sciences 
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.   

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.   

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.  

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.

Caris Life Sciences Media:
Corporate Communications 
CorpComm@CarisLS.com 
214.294.5606  

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-showcase-five-studies-at-the-2026-uscap-annual-meeting-302710422.html

SOURCE Caris Life Sciences

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Caris Life Sciences (CAI) presenting at the 2026 USCAP meeting?

Caris is presenting five studies: one oral presentation and four posters covering sarcomas, melanoma and GIST. According to the company, the work uses their multimodal database (WES, WTS, IHC, and real-world clinical data) and involves collaborators from 20+ cancer centers.

When and where will Caris (CAI) give the oral presentation at USCAP 2026?

The oral presentation is scheduled for March 24, 2026 at 2:00 PM CDT in the Bone and Soft Tissue Pathology session. According to the company, the talk is titled on BCORL1::CREBBP fusions and aggressive ossifying sarcoma with clavicular predilection.

Which poster topics will Caris (CAI) showcase on March 23–24, 2026 at USCAP?

Caris will present posters on melanoma gene fusions, NTRK-rearranged sarcomas, extraskeletal myxoid chondrosarcoma genetics, and PD-L1 in GIST. According to the company, poster sessions occur March 23 and March 24 with listed poster numbers and session times.

How does Caris (CAI) support the presented research at USCAP 2026?

The research is supported by Caris' multimodal clinico-genomic database combining WES, WTS, IHC and real-world clinical data. According to the company, this dataset enabled the molecular and clinicopathologic analyses reported in the five presentations.

Where can attendees find Caris (CAI) materials and abstracts at USCAP 2026?

Research highlights will be available onsite at Caris' exhibit booth #512, and full abstracts will be posted on the company's website after the presentations. According to the company, booth materials will summarize key findings and collaborator contributions.

Do Caris (CAI) presentations at USCAP 2026 involve external collaborators?

Yes, the five studies are collaborative efforts involving more than 20 cancer centers and institutions across the U.S. and Europe. According to the company, these collaborations contributed data and analysis to the oral and poster presentations.